Abstract
Healthy pancreatic β-cells secrete the hormones insulin and amylin in a fixed ratio. Both hormones are lacking in type 1 diabetes, and postprandial glucose control using insulin therapy alone is difficult. This study tested the pharmacodynamic effects of the amylin analog pramlintide and insulin delivered in a fixed ratio over a 24-h period. Patients with type 1 diabetes were stabilized on insulin pump therapy with insulin lispro before a randomized, single-masked, two-way crossover, 24-h inpatient study in which regular human insulin was administered with pramlintide or placebo using separate infusion pumps in a fixed ratio (9 μg/unit). Meal content and timing and patient-specific insulin doses were the same with each treatment. The primary outcome measure was change in mean glucose by continuous glucose monitoring (CGM). Profiles of laboratory-measured glucose, insulin, glucagon, and triglycerides were also compared. Mean 24-h glucose measured by CGM was lower with pramlintide versus placebo (8.5 vs. 9.7 mmol/L, respectively; P = 0.012) due to a marked reduction of postprandial increments. Glycemic variability was reduced, and postprandial glucagon and triglycerides were also lower with pramlintide versus placebo. Gastrointes...Continue Reading
References
Jan 1, 1991·Diabetologia·E HartterR Prager
Sep 1, 1970·Diabetes·F J ServiceW F Taylor
Jul 27, 2001·Current Pharmaceutical Design·C WeyerO G Kolterman
Mar 29, 2002·Diabetes Care·Fred WhitehouseOrville G Kolterman
Jun 25, 2002·Diabetes Technology & Therapeutics·Steven V Edelman, C Weyer
Oct 28, 2003·Diabetes Care·Christian WeyerDavid G Maggs
Oct 23, 2004·Diabetic Medicine : a Journal of the British Diabetic Association·R E RatnerO G Kolterman
Sep 28, 2006·Diabetes Care·Steve EdelmanOrville Kolterman
Sep 2, 2011·Journal of Diabetes Science and Technology·Cynthia R MarlingFrank L Schwartz
Feb 14, 2012·Diabetes Technology & Therapeutics·Sue PenckoferPoul Strange
Jul 20, 2013·Diabetes Technology & Therapeutics·Francesco MichelettoClaudio Cobelli
Jun 5, 2015·Diabetes, Obesity & Metabolism·M C RiddleO G Kolterman
Dec 17, 2016·Diabetes Care·UNKNOWN American Diabetes Association
Nov 23, 2017·Diabetes Care·Thomas DanneMoshe Phillip
Citations
Feb 6, 2019·Current Opinion in Endocrinology, Diabetes, and Obesity·Halis Kaan Akturk, Satish Garg
Jul 26, 2019·PloS One·Navid ResalatPeter G Jacobs
Jan 25, 2020·Diabetes Care·Ahmad HaidarLaurent Legault
Jan 4, 2020·Diabetologia·Amy S Shah, Kristen J Nadeau
Feb 19, 2020·Diabetes Technology & Therapeutics·Melanie Jackson, Jessica R Castle
Feb 19, 2020·Diabetes Technology & Therapeutics·Satish K GargIrl B Hirsch
May 13, 2020·Nature Biomedical Engineering·Caitlin L MaikawaEric A Appel
Mar 21, 2019·Expert Review of Clinical Pharmacology·Laura M NallyWilliam V Tamborlane
May 20, 2020·Clinical Medicine Insights. Endocrinology and Diabetes·Andrew English, Nigel Irwin
Jul 4, 2020·Current Opinion in Endocrinology, Diabetes, and Obesity·Anna CasuUNKNOWN Advancing Care for Type 1 Diabetes, Obesity Network (ACT1ON)
Feb 23, 2020·Diabetes Care·Matthew C Riddle
Sep 1, 2019·Seminars in Nuclear Medicine·Arif SheikhAlan H Maurer
Dec 19, 2020·Diabetes, Obesity & Metabolism·Grit AndersenJ Hans DeVries
Dec 29, 2020·Journal of Diabetes Investigation·Ayako ItoNorio Abiru
Jan 29, 2021·Science Translational Medicine·Caitlin L MaikawaEric A Appel
Feb 18, 2021·Diabetologia·Bernt Johan von ScholtenMatthias von Herrath
Apr 19, 2021·Diabetes Research and Clinical Practice·Matthew C Riddle
May 26, 2021·Journal of Diabetes Science and Technology·Claudio Cobelli, Chiara Dalla Man
Jul 16, 2021·Artificial Organs·Marco InfanteCamillo Ricordi
Jul 29, 2021·Journal of Diabetes Science and Technology·Shylaja SrinivasanEda Cengiz
Aug 28, 2021·Current Diabetes Reports·I H TeohJ D Schofield
Sep 10, 2021·Advanced Science·Caitlin L MaikawaEric A Appel
Aug 25, 2021·Molecular Metabolism·Mark A JarosinskiMichael A Weiss
Dec 2, 2021·The Journal of Clinical Endocrinology and Metabolism·Mark A JarosinskiMichael A Weiss